Search in:

Modern Rheumatology Volume 29, 2019 - Issue 2

Journal homepage

Open access

2,469

Views

CrossRef citations to date

Altmetric

Special Review: IL-6 inhibitor

A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease

Tomohiro KogaUnit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; ;Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Correspondence[email protected]

Remi SumiyoshiUnit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;

Atsushi KawakamiUnit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;

Kazuyuki YoshizakiDepartment of Biomolecular Science and Regulation, The Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan

Pages 302-305 | Received 12 Sep 2018, Accepted 26 Sep 2018, Published online: 14 Jan 2019

Cite this article
https://doi.org/10.1080/14397595.2018.1532383
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (13)

Remi Sumiyoshi, Tomohiro Koga, Shoichi Fukui, Kaori Furukawa, Mamiko Momoki, Kunihiro Ichinose, Shingo Yano & Atsushi Kawakami. (2023) Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types: Implications for the mTOR signaling pathway. Clinical Immunology 256, pages 109798.
Crossref

Magdalena Strach, Piotr Kuszmiersz, Łukasz Chmura & Mariusz Korkosz. (2023) A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report. Clinical Case Reports 11:10.
Crossref

Ronit Sarid, Daniela Dünn-Kittenplon & Maria Luisa Calabrò. 2020. Viral Infections of Humans. Viral Infections of Humans 1 72 .

Tomohiro Koga & Atsushi Kawakami. (2022) Interleukin-6 inhibition in the treatment of autoinflammatory diseases. Frontiers in Immunology 13.
Crossref

David C. Fajgenbaum, Sheila K. Pierson, Karan Kanhai, Adam Bagg, Daisy Alapat, Megan S. Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S. Uldrick & Frits van Rhee. (2022) The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry . British Journal of Haematology 198:2, pages 307-316.
Crossref

Remi SumiyoshiTomohiro Koga & Atsushi Kawakami. (2022) Candidate biomarkers for idiopathic multicentric Castleman disease. Journal of Clinical and Experimental Hematopathology 62:2, pages 85-90.
Crossref

Ronit Sarid, Daniela Dünn-Kittenplon & Maria Luisa Calabrò. 2020. Viral Infections of Humans. Viral Infections of Humans 1 72 .

Daichi Fukaya, Tsutomu Inoue, Yuta Kogure, Hiroshi Kajiyama, Keisuke Ishizawa, Takeru Seto, Hajime Hasegawa, Toshihide Mimura & Hirokazu Okada. (2020) Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases. CEN Case Reports 9:4, pages 318-325.
Crossref

Liu Xiao-dong, Wang Qiu-xu & Liu Wei-xian. (2020) Castleman Disease of the Parotid Gland: A Case Report. Journal of Oral and Maxillofacial Surgery 78:3, pages 400.e1-400.e6.
Crossref

Frits van Rhee, Corey Casper, Peter M Voorhees, Luis E Fayad, Damilola Gibson, Karan Kanhai & Razelle Kurzrock. (2020) Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. The Lancet Haematology 7:3, pages e209-e217.
Crossref

Sakiko Tabata, Tomoaki Higuchi, Seishiro Tatsukawa, Kazuyuki Narimatsu, Hiroaki Takeo, Susumu Matsukuma & Toshimitsu Ito. (2019) Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab. Internal Medicine 58:22, pages 3313-3318.
Crossref

Toshichika Kanagawa, Hiromichi Maeda, Ken Okamoto, Ian Fukudome, Sachi Tsuda, Tsutomu Namikawa, Michiya Kobayashi & Kazuhiro Hanazaki. (2019) Atypical presentation and prolongation of retroperitoneal abscess after emergency surgery for perforated ascending colon cancer in a patient receiving anti-interleukin-6 receptor monoclonal antibody therapy. Annals of Cancer Research and Therapy 27:2, pages 42-45.
Crossref

Mizuna Otsuka, Tomohiro Koga, Remi Sumiyoshi, Momoko Okamoto, Yushiro Endo, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Takashi Igawa, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Niino Daisuke & Atsushi Kawakami. (2019) Rheumatoid arthritis-like active synovitis with T-cell activation in a case of idiopathic multicentric Castleman disease. Medicine 98:18, pages e15237.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease

Articles from other publishers (13)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease

Citations (13)

Articles from other publishers (13)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date